Why Is LIQUIDIA CORP (LQDA) Stock Up Today?

Why LQDA stock is down today

Liquidia Corp (LQDA) fell 10.52% to $78.79 in the session, driven by a combination of a revenue beat and an earnings miss in its Q2 2026 report. The company reported net product sales of $170.4 million, a significant increase from $6.5 million in the same period last year, primarily due to higher YUTREPIA sales. However, the earnings per share of $0.74 fell short of the expected $0.41, contributing to the stock's decline.

What Happened

Liquidia’s Q2 earnings call highlighted strong sales growth for its inhaled treprostinil product, YUTREPIA, with the company capturing approximately 30% of the inhaled prostacyclin market. CEO Roger Jeffs noted the growing demand for the drug, which treats lung disease. Despite the revenue beat, the company missed earnings estimates, which led to a negative market reaction. The earnings call also outlined an expanding investment in the clinical pipeline, including a 327-case study.

The stock's drop followed the release of the earnings report and the subsequent analysis by analysts and investors. While Needham and BTIG maintained Buy ratings and raised price targets to $110 and $111 respectively, LifeSci Capital downgraded the stock to Market Perform with a $90 price target. The mixed analyst sentiment, combined with the earnings miss, contributed to the sharp decline in LQDA shares.

What The Data Shows

The stock traded at a P/E ratio of 379.3, with a market cap of $8.0B and a beta of 0.57. Over the past year, LQDA has traded between $19.90 and $93.61. The company reported a 1936.7% year-to-date revenue increase and a net margin of 7.7%. Notably, insider selling activity has been significant, with 30 sales totaling $140.6 million reported in the last 90 days. The most recent insider transactions occurred on July 27 and July 29, involving key executives and directors.

What To Watch

The stock is currently without scheduled earnings in the near term. Investors should monitor the breadth of analyst coverage and any further developments in the company’s clinical pipeline or regulatory landscape.

Why is LQDA stock up today?

LIQUIDIA CORP (LQDA) is up +7.66% in the latest session. Our newswire has captured 1 story on LQDA across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 62/100). The most recent driver: "Liquidia rises 8% amid broader strength in biotech peers" (Seeking Alpha).

Is LQDA a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of LQDA coverage reads 62/100 over 1 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.